Scandinavian ChemoTech's TSE technology shows great initial pre-trial results in India

Report this content

TSE treatment was performed on eight advanced stage cancer patients who did not respond to conventional treatments. The evaluation showed the desirable goal of tumour shrinkage.

As earlier reported the trials are performed at the large Indian governmentally run hospital chain AIIMS - All India Institute of Medical Sciences. The trial program is part of the India-Sweden Healthcare Innovation Centre, which in turn is a part of a Swedish Indian government healthcare collaboration.

ChemoTech signed an agreement with AIIMS Jodhpur and India-Sweden Healthcare Innovation Centre on 11 November 2021 to set up a Centre of Excellence to bring forward and conduct clinical studies together with the aim of creating clinical data and evidence for the effect of the TSE treatment on various cancers.

 “As a part of pre-study evaluation, we used the TSE technology for treating eight advanced stage cancer patients with different indications who no longer responded to conventional therapies. With TSE, the response obtained was good in all patients and we observed downsizing and local control of the tumour. The treatment was well tolerated by the patients and post procedural management was easy. We can duplicate these results and most likely use this as a weapon to fight against cancer in upcoming studies.” - says Dr Jeewan Ram Vishnoi, Associate Professor, Department of Surgical Oncology, All India Institute of Medical Sciences, Jodhpur, India.

"Even though we are very confident in our TSE technology, it is incredibly joyful and satisfactory to hear of the patients’ improvements, how our technology and the vision of the AIIMS Jodhpur clinical team has come together to achieve these early results."  - says Mohan Frick, CEO of Scandinavian ChemoTech

For further information please contact: Mohan Frick, CEO

+46 (0)10-218 93 00

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00E-mail:

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: